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Background: Bullous pemphigoid (BP) in infants is a rare but increasingly reported autoimmune blistering skin
disease. Autoantibody reactivity is usually poorly characterized. Current guidelines do not address specific aspects of
the infantile form of BP. The objectives of this study are to define clinical and diagnostic characteristics of infantile
BP and develop a treatment algorithm.
Methods: Detailed characterization of a current case series of five infants with BP from our departments.
Comprehensive analysis of all reported cases (1–12 months) with respect to clinical and laboratory characteristics,
treatment and outcome.
Results: In total 81 cases were identified (including our own). The mean age was 4.5 months. Moderately severe
and severe disease was seen in 84% of cases. Involvement of hands and feet was present in all cases.
Immunofluorescence microscopy was comparable with BP in adults. Where analyzed, the NC16A domain of bullous
pemphigoid 180 kDa antigen/collagen XVII (BP180) was identified as the major target antigen. BP180 NC16A ELISA
values in our cohort were significantly higher than in a control cohort of 28 newly diagnosed adult patients.
50% of patients were treated with systemic corticosteroids, 20% with a combination of systemic corticosteroids and
dapsone or sulfapyridine and 10% with topical corticosteroids alone. 14% of patients needed a combination of
multiple immunosuppressants. All but one patient reached remission. Relapses were rare.
Conclusions: Presentation of infantile BP is often severe with blistering of hands and feet present in all cases.
Pathogenesis and diagnostic criteria are comparable to adult BP, yet BP180 NC16A ELISA levels seem to be
significantly higher in infants. The overall disease outcome is favorable. Based on the results of this study we
propose a treatment algorithm for infantile BP.
Keywords: Bullous skin disease, Skin blistering, VaccinationBackground
Bullous pemphigoid (BP, ORPHA703) is an acquired
autoimmune disorder presenting with subepidermal blis-
tering, eosinophilia, and severe itch [1-5]. Its incidence
is increasing [6,7] and it mostly affects the elderly; it is
considered rare in children [8,9]. The first case of BP in
a child was described in 1970 based on immunofluores-
cence diagnosis [10]; the first case of BP in an infant was
described in 1977 [11]. Since then, the number of re-
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article, unless otherwise stated.Nemeth et al. to propose diagnostic criteria for child-
hood BP [12] which included children and adolescents
up to 18 years of age. In 2008, Waisbourd-Zinman et al.
noticed different clinical presentations depending on the
age of affected children [13]. In a literature review, they
showed that the majority of cases of childhood BP oc-
curred in small children under the age of 12 months and
that these infants presented with a particular clinical pic-
ture. All affected infants had acral involvement with or
without generalized blistering. The distribution in later
childhood was far less uniform and included a subgroup
of children with localized genital BP, a presentation not
described in infants. These clinical differences led to the
distinction of infantile versus childhood BP [13].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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but serological tests were not performed systematically
in many of the reported cases [13]. The gold standard
for diagnosis is direct immunofluorescence microscopy
(DIF). However, little information is available on the in-
terpretation of ELISA levels [14], inflammatory markers
or blood cell counts in infants. Further knowledge, espe-
cially about the relevance of ELISA levels might help to
assess disease severity and thus influence the choice of
medication or duration of treatment.
Concerning the treatment of infantile BP, first line treat-
ment usually consists of topical or systemic corticoste-
roids. However, there are no stringent therapeutic criteria
and there has been very little discussion on the different
options for second line treatment. Furthermore, in clinical
consensus guidelines on treatment of BP, there is very lit-
tle, if any, information on treatment in infants [15-18].
Here, we report the diagnostic results and disease
course of five children with infantile BP in our care and
a comprehensive analysis of all cases reported in the lit-
erature. Based on these data – and taking into account
the published guidelines for adults as well as special cir-
cumstances of treating small infants – we propose a first
treatment algorithm for infantile BP.
Methods
Infantile BP cohort and adult BP control cohort
Five infantile BP patients presented at or were referred
to our departments. They were included in this study
after we obtained parental informed consent for partici-
pation and took blood and skin samples for diagnostic
and research purposes. As a control, BP180 NC16A
ELISA levels of a cohort of 28 adult BP patients that
were newly diagnosed in the same time period were de-
termined after informed consent was provided. All in-




Hematoxylin eosin staining of formalin fixed, paraffin em-
bedded tissue sections was performed using standard
methods. DIF and indirect immunofluorescence micros-
copy (IIF) were performed as previously described [19-21].
FITC labeled antibodies used for DIF were anti human
IgG, IgA, IgM and C3c (Dako, Hamburg, Germany) at a
dilution of 1:200, 1:50, 1:50 and 1:500 respectively. For IIF
on salt-split skin, patient sera were diluted 1:10, secondary
antibodies used were FITC labeled anti human IgG and
IgA (Dako, Hamburg, Germany) at a dilution of 1:100 and
1:25 respectively. Immunoblotting of normal human kera-
tinocyte extracts with patient sera at a 1:20 dilution and
alkaline phosphatase anti human IgG (Sigma-Aldrich,
Taufkirchen, Germany) secondary antibody was performedas previously described [20,21]. ELISA kits for the detec-
tion of BP180- and bullous pemphigoid 230 kDa antigen
(BP230)-specific antibodies (MBL, Nagoya, Japan) were
used according to the manufacturer’s protocol with the
cut-off at 9 U/ml.
Statistical analysis
Boxplot descriptive statistics of BP180 NC16A ELISA
values were performed using GraphPad Prism software
(GraphPad Software, La Jolla, CA).
Literature search
We searched all retrievable English- and foreign-language
medical literature using PubMed, PubMed Central, EMBASE,
and Google Scholar databases as well as literature cited in
the obtained reports. Relevant information was extracted
and reviewed to avoid duplications of reports. We in-
cluded only infants up to 12 months in our review and ex-
cluded cases of neonatal BP.
Results
Patient cohort/index case
The clinical and laboratory findings of the five patients in
our cohort are presented in Table 1. Patient 1 (index case)
showed characteristic infantile BP and was the most se-
verely affected; his treatment proved to be the most chal-
lenging. He is therefore presented in more detail. The
previously healthy three-month-old boy of Algerian des-
cent presented with a one-week history of small blisters
on hands and feet and urticarial plaques on the trunk.
Impetigo had been ruled out at a nearby hospital but no
diagnosis had been made. He had received one oral vac-
cination against Rotavirus one month prior. No other vac-
cinations had been given. Apart from mild eczema, there
was no family history of skin disease. Over the course of
one week the lesions increased in number and size. The
patient was irritable and not feeding well.
On clinical examination, he had firm blisters and bullae
predominantly on the hands and feet, as well as urticarial
plaques with an elevated rim and a dusky center. These
plaques were predominantly located on the trunk but also
present on all other areas of the body (Figure 1A, B). The
Nikolsky sign was negative; there were no mucosal lesions.
Blister fluid microscopy demonstrated mainly eosino-
phil granulocytes; cultures from blister fluid remained
sterile. Blood testing, including a full blood count,
showed normal values with the exception of a peripheral
eosinophilia of 10%. Punch biopsies were performed for
histologic and immunofluorescence analyses. Histology
showed dermal edema and eosinophil inflammatory in-
filtrate (not shown). DIF revealed linear staining of IgG
(Figure 1E) and complement component C3 (Figure 1F)
along the basement membrane zone. IIF microscopy
showed circulating IgG autoantibodies binding to the
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1) 3/M Generalized + DIF: IgG, C3 (BM) Anti BP180 10.4 × 109/l (10) a) Prednisolone Initially rapid response
with disease control
Family history of atopy
HF+ IIF: IgG (BR) 136 U/ml At relapse: 2 mg/kg/d→ 1 mg/kg/d Relapse within 2 weeks





IB: 180kD pos. (norm < 9) 54 × 109/l (52) b) Dapsone 2 mg/kg/d Slow response after relapse,
need for multiple medications
4 weeks prior
At relapse: Tc >1000 × 109/l c) IVIG 1 g/kg × 3 Response to dapsone after
2.5 weeks




2) 3/M Localized with few
disseminated lesions HF+
- DIF: IgG, C3 (BM) Anti BP180 16.1 × 109/l (23) a) Topical Prednicarbate Good response to topical
treatment within days
IIF: IgG (BR) 90 U/ml (mid-potency corticosteroid) No relapse
IB: 180kD pos. (norm < 9) Duration of treatment:
4 weeks
Anti BP230 neg.
3) 4/M Generalized - DIF: IgG, C3 (BM) Anti BP180 23.4 × 109/l (20) a) Prednisolone Complete remission
within 1 week
Vaccination 4 weeks prior
HF+ IIF: IgG (BR) 156 U/ml 2 mg/kg/d→ 1 mg/kg/d Weaning of steroids
within 3 months
(DPTP, HiB, HepB, Rotavirus)
IB: 180kD pos. (norm < 9) b) Dapsone 1.5 mg/kg/d No relapse
Anti BP230 neg. Duration of treatment:
6 months
4) 3/F Generalized - DIF: IgG, C3 (BM) Anti BP180 25.1 × 109/l (13) a) Prednisolone Slow response to
prednisolone 1 mg/kg
Rotavirus vaccine




IB: 180kD pos. (norm < 9) b) Systemic betamethasone No relapse upon
glucocorticoid tapering
Arterial hypertension
Anti BP230 neg. 0.3 mg/kg/d Complete remission under
dapsone 0.5 mg/kg/d
Myocardial hypertrophy
c) Dapsone Treatment ongoing → Propranolol














Table 1 Clinical and laboratory findings of the patient cohort (Continued)
5) 7/M Generalized - DIF: IgG, C3 (BM) Anti BP180 27.3 × 109/l (9) a) Prednisolone 1→
0.5 mg/kg/d
Rapid response to oral
betamethasone
HF+ IIF: IgG (BR) 154 U/ml Tc 599 × 109/l b) Systemic betamethasone Full remission after 2 months
IB: 180kD pos. (norm < 9) 0.4 mg/kg/d→ 0.2 mg/kg/d No relapse
Anti BP230 neg. c) Dapsone 0.5 mg/kg/d Treatment ongoing
HF: Hands/Feet + present, − not present; OM: Involvement of oral mucosa; + present, − not present; DIF: Direct immunofluorescence microscopy; IIF: Indirect immunofluorescence microscopy; IB: Immunoblot;
BM: basement membrane; BR: Blister roof; WBC White blood cell count; Eos: eosinophil granulocytes; Tc: thrombocytes; DPTP: Diphteria, Pertussis, Tetanus, Poliovirus; HiB: Haemophilus influenzae type b;
HepB: Hepatitis B.














Figure 1 Clinical and diagnostic hallmarks of infantile BP. Patient 1 at initial presentation: A, urticarial plaques on the trunk. B, firm blisters
and bullae on the hands and feet. C, D, Patient 1 after relapse with severe blistering on 2 mg/kg prednisolone daily. Direct immunofluorescence
microscopy: E, linear IgG and F, linear C3c depositions along the basement membrane zone (white arrows, 200× original magnification). G, indirect
immunofluorescence on salt-split skin reveals circulating IgG antibodies that bind to the blister roof, which is diagnostic for BP (white arrows, 200×
original magnification).
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testing with recombinant NC16A domain of BP180 was
strongly positive (136 U/ml, norm <9 U/ml). The find-
ings were diagnostic for BP.
Initially, we treated with potent topical corticosteroids
and oral antihistamines, which did not lead to significant
improvement. After confirmation of the diagnosis, a
treatment with prednisolone up to 2 mg/kg/day was ini-
tiated. After a brief period of clinical improvement and
disease control, the patient had a respiratory tract infec-
tion in the course of which he developed severe blister-
ing. At this time he was still on 2 mg/kg prednisolone
daily (Figure 1C, D). Peripheral blood count showed
leucocytosis with a maximum of 54 G/l (52% eosinophils)
and significant reactive thrombocytosis (>1000 G/l) with
signs of increased coagulation activity necessitating treat-
ment with acetylsalicylic acid. The ELISA value for BP180-specific antibodies at this point was 189 U/ml. After
confirming normal glucose-6-phosphate dehydrogenase
levels, we added dapsone at a maximum dose of 2 mg/kg
daily, controlling for the development of methemoglobinemia.
As the blistering continued to progress, we added intravenous
immunoglobulins (IVIG) 1 g/kg three times. Yet the patient
developed more cutaneous and additionally intraoral blis-
ters causing refusal of oral intake. He also developed per-
sistent hoarseness, but laryngeal involvement of the BP
could be excluded.
After two weeks of worsening, we added oral myco-
phenolate mofetil (MMF) at a dose of 625 mg/m2 twice
daily (MMF local dosing regimen, note that recom-
mended standard dose in children is 600 mg/m2 twice
daily). Within days, the patient’s skin improved and the
number of new lesions decreased. We interpreted this
improvement as delayed response to dapsone rather
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weeks to set in. Over the following weeks, we slowly
weaned the patient off systemic corticosteroids and then
reduced the MMF dose in two steps over two months.
After another two months of clinical remission, we also
stopped treatment with dapsone. After 12 months the
patient was off all medication. Anti-BP180 antibody
values significantly decreased over the course of three
months, parallel to clinical improvement. Also, the num-
ber of leukocytes (including eosinophils) and thrombo-
cytes decreased and normalized. At the time of
submission, the patient had been free of symptoms for
two years. Due to parental fear of relapse, the patient
had not received any further vaccinations.
Analysis of all reported infantile BP cases, including own
patient cohort
Clinical characteristics
The literature review of all obtainable reports between
the years 1977 and 2013 including our own cases re-
vealed 53 reports [8,11-14,22-68] with a total of 81 cases
of BP occurring in children within the first year of life
but beyond the neonatal period (Additional file 1: Table
S1). While very few cases were reported before the year
2000, there has been a significant increase since then
(Additional file 2: Figure S1). The mean and median age
was approximately four months with 64% of casesTable 2 Clinical characteristics of all reported infantile BP cas
No of cases N = 81
Mean (median) age/age range 4.5 (4) m
Gender M/F 39/38 (4
Extent of skin in involvement
• Localized/mild disease (+/− few disseminated plaques) N = 10 (1
• Generalized/moderately severe and severe disease N = 68 (8
• N/A N = 3 (3.7
• Involvement of hands and feet N = 81 (1
Involvement of oral mucosa (with generalized disease) N = 12 (1
No of children vaccinated prior to onset N = 25 (3
• DPTP +/− others, N = 22
• Rotavirus, N = 2
• DPTP plus Rotavirus N = 1
No of patients with a relapse N = 12 (1
Outcome
• Cured N = 76 (9
• In remission under treatment at time of report N = 3 (3.7
• Still symptomatic at time of report N = 1 (1.2
• Death N = 1 (1.2
N/A: Not Available; DPTP: Diphteria, Pertussis, Tetanus, Poliovirus.between three to five months. The gender ratio male to
female was 39 to 38. In four cases gender was not stated.
Moderately severe and severe (generalized) disease
(>10% body surface area – BSA) was seen in 83.9% of
cases (n = 68 of 81). All children showed at least some
involvement of the hands and feet. Mucosal blistering
was present in 14.8% of cases (n = 12 of 81); four of
these patients had severe disease (Table 2).
98% (n = 79 of 81) of children affected had previously
been healthy. One patient had a congenital T-cell lym-
phocytopenia and one child had been diagnosed with
Hyper IgE-syndrome. The general condition at the time
of presentation was good in the majority of cases; some
patients were irritable, likely due to pruritus. However,
one child with a very delayed initiation of appropriate
treatment presented with significant morbidity, includ-
ing severe weight loss, dehydration and failure to thrive,
as well as developmental delay [41]. One of our own pa-
tients was also severely affected during a relapse where
he refused oral intake and lost weight (see index case
above). Both children improved quickly once sufficient
treatment was established.
Twenty five children (30.8%) had been vaccinated within
days or weeks prior to the onset of disease, the majority
with the standard mix of passive vaccines recommended in
this age group. Two of our five own cases had received a









All children with oral lesions had generalized
skin involvement
Severe disease N = 5
0.8%)
Latency between vaccination and onset of
disease: 1 day - 4 weeks
4.8%)
3.8%)
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In two children a febrile infection was reported prior to the
onset of disease [37] or prior to a relapse [27], this report.
Pathophysiology and diagnostic features
Histology, if reported, showed dermal edema, an inflam-
matory infiltrate dominated by eosinophils and subepider-
mal blistering. DIF showed IgG and/or C3 along the
basement membrane in 72 cases (90%), in 12 cases (15%)
there were additional IgA deposits, in four cases there
were IgM- and in one case IgE-deposits. In immunoblot
analyses reported in 20 patients, 15 sera recognized a
180 kDa protein, five sera recognized a 230 kDa protein,
and one serum both.
ELISA values were reported in only 21 (25.9%) cases.
All of these patients had antibodies against the NC16A-
domain of BP180; two also had additional anti-BP 230
antibodies. Comparison of ELISA values of reported
cases from different centers is not fully possible because
of different commercial and non-commercial ELISA sys-
tems used. In our own cohort, BP180 NC16A ELISA
values in infantile patients were significantly higher than
in a control group of 28 adults newly diagnosed with BP
in our center in the same time period (Figure 2). Ex-
tremely high values in our cohort and in reported pa-
tients seemed to be associated with more extensive
disease and the need for systemic treatment.
A blood cell count was reported in 37 patients, the
mean white blood cell count was 23.9 G/l (range <10-Figure 2 ELISA values in infantile and adult BP. Anti-BP180 ELISA
values in our infantile BP cohort were significantly higher, compared
to a control group of newly diagnosed adult BP patients (normal
value <9 U/ml; boxplot analysis; whiskers: minimum and maximum
values; bottom and top of boxes: first and third quartiles; band inside
box: median; cross: mean).120G/l, median 19.4). The percentage of eosinophils had
a mean of 23% (range 7-66%, median 19%).
Treatment modalities
The majority of patients were treated with systemic cortico-
steroids (50.6%) with or without additional erythromycin or
other antibiotics. 19.8% of patients were treated with a
combination of systemic corticosteroids and dapsone or
sulfapyridine, and 9.9% were treated with topical corticoste-
roids alone. 13.7% of patients (n = 11) needed a combin-
ation of multiple agents (Table 3). All but one patient
reached remission eventually. However, the patient with
concomitant congenital T-cell lymphocytopenia died
from unknown cause three months after having re-
ceived two doses of rituximab for severe disease. Re-
lapses were not common (14.8%, n = 12) (Table 3 and
Additional file 3: Table S2).
Discussion
Infantile BP is considered very rare. Prospective studies
are therefore difficult to perform. Incidence in Israel was
estimated to be 2.36:100,000 per year [13]; however, in
most countries no central registry exists and the disease
might be under-recognized. We present a detailed
characterization of a current cohort of five infants with
BP from our departments. Furthermore we performed a
comprehensive analysis of all cases reported in the litera-
ture (age 1–12 months) with respect to clinical and la-
boratory characteristics and treatment modalities. Taken
together the results allow for the following conclusions.
Diagnostic features
Laboratory test results in infantile BP generally resemble
those in adult BP. Linear IgG and/or C3 depositions at the
basement membrane in DIF are the diagnostic hallmark.
Autoantibody profiles, as detected by various methods, are
comparable to those in adults with BP [69]: autoantibodies
against the NC16A domain of BP180 are more frequent
than anti-BP230 antibodies.
We propose the following minimal diagnostic criteria
for infantile BP: typical clinical picture (urticarial plaques
and blisters, acral distribution) and linear IgG and/or C3
deposition at the basement membrane in DIF. Further
diagnostic pointers are the presence of serum autoanti-
bodies against BP180 and/or BP230. and – even though
less specific – subepidermal blistering with an eosinophil
rich inflammatory infiltrate in conventional histology.
Even though ELISA results were only reported in a mi-
nority of cases, and different test systems used do not
allow for direct comparison, the reported autoantibody
levels in infants seem fairly high. Comparing ELISA
values of our five infants with a control group of 28
adults newly diagnosed with BP in our center in the
same time period, we found that the mean and median
Table 3 Treatment Modalities of Infantile BP Patients
Treatment No of cases (% of total N = 81) Comments
Topical corticosteroids alone N = 8 (9.9%) Good response
Topical corticosteroids + IVIG N = 1 (1.2%) Several relapses for one year
Topical corticosteroids + erythromycin N = 1 (1.2%) Good response
Systemic +/− topical corticosteroids (+/− antibiotics) N = 41 (50.6%) Good response
Systemic corticosteroids + dapsone/ sulphapyridin
(+/− antibiotics)
N = 16 (19.8%) Good response
Dapsone/ sulphapyridin alone N = 2 (2.5%) One relapse under treatment.
Same treatment was attempted in
one other patient without success, so
steroids were added.
No treatment N = 1
N/A N = 1
Corticosteroids +/− dapsone plus other medications
due to poor response
N = 11 (13.7%)
• Azathioprine N = 1 No response
• Cyclosporine N = 2 Good response in N = 1
Partial response in N = 1
• Mycophenolate mofetil N = 7 Moderate response in N=7
• Erythromycin and nicotinamide N = 8 Good response in N = 3
Partial / uncertain response in N = 5
• IVIG N = 8 Good response in N = 2
Partial/ uncertain response in N = 6
• Rituximab N = 3 Good response N = 2.
Partial response N = 1.
One sudden death in one of those
two patients after three months
(child had congenital immune
deficiency).
• Omalizumab N = 1 Good response
IVIG: Intravenous immunoglobulins.
Table 4 Important Differential Diagnoses of Infantile BP
Autoimmune blistering skin diseases • Linear IgA dermatosis
• Epidermolysis bullosa acquisita
Hereditary • Epidermolysis bullosa
• Porphyria




• Insect bite like reaction of
hematologic malignancy
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were significantly higher. These ELISA values had been
measured with the same test system (see Methods).
The clinical relevance of antibody testing in infantile
BP has been contested [14]. Nevertheless – when tested –
patients with a more recalcitrant disease course demonstrated
high autoantibody levels. In our cohort, higher values at
presentation correlated with the need for more aggressive
and longer-term treatment, and values increased before
relapses. Therefore, it appears reasonable to take into ac-
count the levels of BP180-specific autoantibodies in in-
fantile BP when making treatment decisions.
Patient characteristics/clinical features
At disease onset, the mean age of children was around
four months. As opposed to previous reports [13], there
was no significant female predominance.
No common trigger was identified. A large number of pa-
tients had either been vaccinated or suffered an infection
prior to the onset or relapse of disease (Table 2, Additional
file 1: Table S1 and Additional file 3: Table S2). The type
of infection or vaccine varied. It can be speculated thata modulation of the immune system might play a role in
triggering or unmasking an underlying subclinical BP.
Nevertheless, especially due to the high number of infants
receiving vaccination, this association might be purely coin-
cidental and we believe that the term postvaccination in-
fantile BP should be used with caution.
Cases of adult BP associated with malignancy exist,
even though the causal relation remains unclear. In
Schwieger-Briel et al. Orphanet Journal of Rare Diseases  (2014) 9:185 Page 9 of 12contrast, no case of infantile BP in relation with a malig-
nant neoplasm has been reported. Furthermore, unlike
in adult BP [70,71], drugs do not seem to play a major
role in triggering infantile BP.Figure 3 Step-by-step diagnostic and treatment algorithm. The algorit
initial treatment and specific aspects of steroid sparing agents.Within the age group of four weeks to 12 months, the clin-
ical picture was moderately severe to severe (generalized) in
over 80% of cases. Acral blistering was present in all chil-
dren, while mucosal involvement was uncommon. Inhm was developed taking into account disease severity, response to
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There was no case of isolated genital infantile BP. Taken
together, involvement of the hands and feet can be consid-
ered as a clinical hallmark and diagnostic clue of infantile
BP. This is in contrast to childhood and adult BP [1,4,69].
Important differential diagnoses of infantile BP are listed
in Table 4.
Most infants were doing well at the time of presenta-
tion despite some irritability, likely due to pruritus.
However, individual children with significant morbidity
including difficulty breathing and feeding, and weight
loss, have been reported.
Even though initial presentation is often severe, the
prognosis of infantile BP is excellent, with all but one
patient reaching complete remission. That child had
only been followed up short-term at the time of publica-
tion [8] and subsequent remission is possible. One infant
passed away shortly after having been discharged from
hospital. This child had received several doses of rituxi-
mab and had an underlying immune deficiency, which
might have played a role.
The number of relapses was low. It seems that relapses
can be triggered by infections or that they occurred in pa-
tients where tapering of corticosteroids was started early.
Also, relapses were more frequent in patients who did not
receive systemic corticosteroids (Additional file 3: Table S2).
Once the disease has been controlled for several months,
the likelihood of a relapse is extremely small.
Treatment algorithm
In contrast to adult BP, no treatment guidelines for infant-
ile BP exist [15-18,72], and there has been little discussion
on possible criteria for choosing the right treatment. After
a comprehensive analysis of reported treatments in all
published cases of infantile BP – together with lessons
learned from our own cohort – we propose a first treat-
ment algorithm. This step-by-step diagnostic and treat-
ment algorithm takes into account disease severity,
response to initial treatment and specific practical aspects
of steroid sparing agents. It is based on general experience
with the different medications in infants and the treatment
recommendations published for adult BP (Figure 3).
After the diagnosis is established, all patients should
receive treatment with mid- to high-potency topical cor-
ticosteroids. Children with moderately severe or severe
disease (generalized, >10% BSA) usually require add-
itional treatment with systemic corticosteroids. If the
treatment response is slow or high doses of corticoste-
roids are needed for disease control, additional steroid
sparing agents should be considered. Dapsone seems to
be the agent of choice as it is usually well tolerated,
effective, and is frequently used for other autoimmune
blistering diseases of infancy and childhood, such as lin-
ear IgA dermatosis. Other steroid sparing agents usedare IVIGs and MMF. Little or no experience exists for
erythromycin-, methotrexate-, cyclophosphamide or aza-
thioprine treatment in infants with BP. Rituximab is to
be reserved as rescue treatment for the most severe
cases [49,67]. The full potential and dosing of omalizu-
mab in infantile BP warrant further investigation [56,73].
After clinical remission for several months, treatment
discontinuation can be considered. In our experience
ELISA autoantibody values can take a long time to
normalize and are therefore not always helpful for decid-
ing when to end treatment.
Conclusions
Infantile BP is considered a rare disorder; however an in-
creasing number of reports during the last years show
that it might have been under-recognized. As the dis-
order is not well known to general pediatricians and der-
matologists, most infants are not promptly diagnosed
and undergo multiple examinations before establishment
of the correct diagnosis.
Infantile BP presents with urticarial plaques and blis-
ters. Involvement of hands and feet is present in all
cases. The clinical picture of infantile BP is characteris-
tic. It is therefore a realistic aim to make the diagnosis
early, avoid unnecessary diagnostic measures, and treat
appropriately to avoid severe morbidity.
Pathogenesis and diagnostic criteria are comparable to
adult BP, yet ELISA levels seem to be higher in infants.
The overall disease outcome is favorable. Based on the
results of this study we have established a first step-by-
step diagnostic and treatment algorithm, taking into ac-
count disease severity, response to initial treatment and
specific aspects of steroid sparing agents.
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